Clinical Trial Update: A Phase 4 Study of Brodalumab (KHK4827) in Subjects With Moderate to Severe Plaque Psoriasis [Phase 4]

View source ↗

Summary

Phase 4 trial of brodalumab (KHK4827) for moderate to severe plaque psoriasis was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• brodalumab (brodalumab)

Snippet

Sponsor: Kyowa Kirin Co., Ltd. | Conditions: Moderate to Severe Plaque Psoriasis | Phase 4 | Status: WITHDRAWN